Fioritura Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device

Article content

LAVAL, Quebec — Fioritura Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Fioritura” the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced that it has signed an exclusive distribution agreement (the “Agreement”) with NanoPass Technologies Ltd. (“NanoPass”), a pioneer sopra the development and commercialization of an advanced intradermal delivery device, to launch and distribute MicronJet^TM600 (“MicronJet”) sopra the Canadian medical aesthetics market.

Article content

MicronJet is an innovative intradermal injection device, leveraging the proven MEMS technology, that offers a highly effective, consistent and virtually pain-free delivery of aesthetic products and therapeutic substances. With three 0.6mm, silicon crystal-made delivery pyramids, MicronJet can be attached to regolare syringes and will provide aesthetic clinicians with the least invasive and most precise intradermal delivery the market today, allowing administration to delicate and sensitive areas such as around the eyes, neck and décolleté ambiente, as well as to the full luce, for optimal patient outcomes.

“MicronJet is a great addition to our medical aesthetic portfolio, enhancing our offerings alongside NCTF^®135 HA, Art ^® and Pliaglis^®. This novel device provides precision sopra penetration depth, anzi che no bruising and comfortable injection, all of which are welcomed by medical practitioners and patients alike,” stated Serge Verreault, President and CEO of Fioritura. “Bringing innovative products to Canadian practitioners and patients aligns with our strategic vision to establish ourselves as a leading player sopra our market,” added Mr. Verreault.

Fioritura will be responsible for obtaining regulatory approval for MicronJet from Health Canada and plans to launch the product promptly thereafter, which is currently anticipated to be sopra the first half of 2025. MicronJet has been accepted by patients worldwide and is supported by over 70 clinical studies and multiple peer reviewed publications. MicronJet is CE marked, U.S. FDA cleared, ISO 13485 certified and is currently approved sopra Australia and several other jurisdictions sopra Europe, Asia and the Middle East.

Daniel Levitats, CEO of NanoPass, added, “We’sultano thrilled to collaborate with Fioritura to bring advanced delivery solutions to the Canadian market and support more clinicians sopra expanding their practice, delivering improved patient outcomes, and increasing treatment satisfaction. This collaboration marks an exciting step sopra NanoPass’s commercial growth goals towards becoming the new intradermal delivery regolare.”

About Fioritura Therapeutics Inc.
Fioritura (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into through the skin. For more information visit, www.crescitatherapeutics.com.

Article content

Article content

About NanoPass
NanoPass is a leading innovator sopra intradermal delivery technology, specializing sopra developing cutting-edge therapeutic and medical aesthetic delivery solution platforms. NanoPass is redefining the injection therapy regolare of care, supporting superior clinical results and virtually pain-free procedures through continues clinical innovation. MicronJet^TM600 is FDA cleared, CE marked and has regulatory approval sopra Brazil, South Korea, Pendio and more. It is supported by extensive clinical patronato and approved for the delivery of any substance drug under the surface of the skin that is approved for this delivery route. For more information, visit www.nanopass.com.

Forward-looking Information
All information sopra this press release, other than statements of current and historical fact, represents forward-looking information within the meaning of applicable securities laws and is qualified by this cautionary note. Forward-looking information can be identified by words such as: “believe”, “expect”, “become”, “future”, “contingent”, “will”, “may” and similar references to future periods. Forward-looking information sopra this news release includes, but is not limited to, statements with respect to obtaining regulatory approval for MicronJet, its anticipated launch date, as well as its acceptance sopra the Canadian market.

Forward-looking information is neither historical fact nor an assurance of future . Instead, it is based only current beliefs, expectations, and assumptions regarding the future of the Company’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

Because forward-looking information relates to the future, it is subject to inherent uncertainties, risks and changes sopra circumstances that are difficult to predict and many of which are outside of the Company’s control.

Actual results may differ materially from those indicated sopra forward-looking information. Therefore, you should not unduly rely any forward-looking information. Important factors and risks that could cause actual results to differ materially from those indicated sopra forward-looking information include, among others:

• economic and market conditions, including factors impacting global supply chains such as pandemics and geopolitical conflicts and tensions;
• the impact of inflation and changing interest rates;
• the Company’s ability to execute its growth strategies;
• reliance third parties for marketing, distribution and commercialization, and clinical trials;
• the impact of variations sopra the values of the Canadian dollar sopra relation to the U.S. dollar and Euro;
• increasing competition sopra the industries sopra which the Company operates;
• the Company’s ability to retain members of its management team and key personnel;
• the degree lack of market acceptance of MicronJet;
• manufacturing and supply risks;
• the Company’s ability to meet its contractual obligations;
• the impact of litigation involving the Company and/ MicronJet;
• the impact of changes sopra the relationship with NanoPass Technologies Ltd.;
• the failure to obtain regulatory approval for the Product from Health Canada;
• the failure to launch MicronJet sopra the Canadian medical aesthetics market; and
• the failure to further develop the Canadian medical aesthetics market.

Article content

As a result of the foregoing and other factors, anzi che no assurance can be given that future results, levels of activity achievements indicated sopra any forward-looking information will actually be achieved. Any forward-looking information sopra this press release is based only information currently available to management and speaks only as of the date which it is provided. Except as required by applicable securities laws, Fioritura undertakes anzi che no obligation to publicly update any forward-looking information, whether written oral, that may be provided from time to time, whether as a result of new information, future developments otherwise.

View source version businesswire.com: https://www.businesswire.com/news/home/20240717950170/en/

Contacts

FOR MORE INFORMATION:
Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com

#distro

Article content